Overcoming challenges in refining the current generation of coronary stents

Matrix-Binding, N-Cadherin–Targeting Chimeric Peptide Inhibits Intimal Thickening but Not Endothelial Repair in Balloon-Injured Carotid Arteries

“…antiplatelet therapy. 5,6 Although advances in pharmacological and stent technology have enabled a reduction in stent failure, restenosis and stent thrombosis can still occur, and given the large number of percutaneous interventions performed annually, addressing these complications remains relevant. 7 Further, whereas drug-eluting stents are commonly used in coronary arteries, balloon angioplasty alone is often used in peripheral arteries, with a consequent elevation in the incidence of restenosis.…”

“… 4 The use of drug-eluting stents can effectively attenuate restenosis, but the cytotoxic drugs commonly used (ie, paclitaxel or sirolimus) contribute to endothelial cell (EC) dysfunction and death, leading to in-stent thrombosis and necessitating prolonged antiplatelet therapy. 5 , 6 Although advances in pharmacological and stent technology have enabled a reduction in stent failure, restenosis and stent thrombosis can still occur, and given the large number of percutaneous interventions performed annually, addressing these complications remains relevant. 7 Further, whereas drug-eluting stents are commonly used in coronary arteries, balloon angioplasty alone is often used in peripheral arteries, with a consequent elevation in the incidence of restenosis.…”